arrow
E

Elena Conca

fondazione irccs - istituto nazionale dei tumori
H指数:19
被引数:2,028

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

帕尼单抗(panitumumab)再治疗随后使用瑞戈非尼(regorafenib)与相反顺序在RAS和 BRAF野生型循环肿瘤DNA的化学耐药性转移性结直肠癌患者中的比较:GONO进行的PARERE研究

2025-10-180
OAAI
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer

基因组不稳定性及CCNE1扩增作为分层高级别浆液性卵巢癌的新兴生物标志物

2025-08-070
OA
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
2024-09-010
PRE
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
2024-02-094
OAAI
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
2023-11-011
OAAI
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei

腹膜假性粘液瘤中A2AR的表达和免疫抑制环境与KRAS和GNAS突变无关

2023-07-204
OAAI
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
2022-04-083
OAAI
SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor
2022-01-0410
OAAI
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
2019-01-0115
OAAI